Aktienanalyse zu Humana Inc (HUM)HUMHumana Inc

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Humana Inc is a good buy right now due to its recent performance and strong fundamentals. The stock is currently priced at $413.16, which is below the analyst price target range of $475 to $525, indicating potential upside. Additionally, the company has improved its Medicare Advantage ratings significantly, with 95% of its members now in plans rated four stars or higher, which could lead to an estimated $3.6 billion in additional revenue. However, the main risk is the recent decline in stock price, with a 5-day change of -4.33%.

19 analysts cover HUM: 12 rate it Buy, 7 Hold and 0 Sell. The average price target is 290.39.